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2ABSTRACT
Macrophage inhibitory cytokine 1 (MIC-1), a divergent member of the
transforming growth factor beta superfamily, plays a role in progression of number of
cancers including breast, gastric, prostate and colorectal carcinomas. Serum MIC-1 levels
are elevated in patients with metastatic prostate, breast and colorectal carcinomas. In vitro
studies have revealed cell type specific role for MIC-1 in senescence and apoptosis. MIC-
1 activates the survival kinase AKT/PKB in neuronal cells. Depending on cell type, it
activates or represses MAP kinases ERK1/2. Mechanisms responsible for increased MIC-
1 expression in cancers and consequences of MIC-1 overexpression, however, are not
known. In this study, we show that AKT/PKB directly regulates the expression of MIC-1
in breast cancer cells. Sequences within –88 to +30 of the MIC-1 promoter are required
for AKT-mediated induction of MIC-1. This region of the promoter contains two SP-1
binding sites (SP-1B and SP-1C), which bind to SP-1 and SP-3 proteins. Mutation of SP-
1C but not SP-1B reduced AKT-mediated activation of MIC-1. MIC-1 increased basal
ERK1 phosphorylation and prolonged estrogen-stimulated ERK1 phosphorylation in
MCF-7 breast cancer cells without altering the phosphorylation status of AKT/PKB.
Immunohistochemistry with MIC-1 antibody revealed MIC-1 expression within cancer
cells of primary breast cancer and in MCF-7 xenografts. Furthermore, a limited analysis
of RNA from primary breast cancers revealed overexpression of MIC-1 in tumors
compared to normal tissues. These results suggest that AKT/PKB through MIC-1 can
regulate ERK1 activity and MIC-1 expression levels may serve as a surrogate marker for
AKT activation in tumors.
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3INTRODUCTION
The serine/threonine kinase AKT/PKB is a major cell survival kinase for a
number of cell types including breast cancer cells [1]. It is activated by growth factors
including epidermal growth factor, platelet derived growth factor and heregulin [1].
Constitutive activation of AKT is observed in a number of cancers including breast
cancer [2-4]. Constitutively active AKT along with telomerase can immortalize
mammary epithelial cells [5]. In transgenic mouse model, constitutively active AKT
alone induces hyperplasia and collaborates with ErbB2 to induce mammary
carcinogenesis [6,7].  It is also suggested that AKT/PKB phosphorylates Raf kinase in
breast cancer cells leading to inhibition of Raf-MEK-ERK signaling and shifting of
cellular response from cell cycle arrest to proliferation [8,9].
We recently reported AKT/PKB-mediated activation of estrogen receptor alpha
(ERa) and tamoxifen resistance in MCF-7 cells [10].  MCF-7 cells engineered to
overexpress constitutively active AKT showed ~5 fold increase in the expression of
macrophage inhibitory cytokine (MIC-1). MIC-1 (also known as NAG-1, GDF-15, PDF,
PLAB and PTGFB) is a divergent member of transforming growth factor superfamily and
is considered as a biomarker for p53 pathway activation [11-13]. Although in vitro
studies suggested anti-proliferative and pro-apoptotic functions of MIC-1 in breast,
prostate, colon cancers as well as in glioblastomas, analysis of serum samples of patients
showed a striking correlation between elevated MIC-1 levels and metastatic progression
of colorectal, breast and prostate cancers [14-21]. MIC-1 level is also elevated in the
serum of patients with pancreatic ductal adenocarcinoma [22]. MIC-1 increases
invasiveness of gastric cancer cells by upregulating the expression of urokinase
plasminogen activator [23]. Elevated levels of serum MIC-1 is associated with
cardiovascular events whereas lower level of MIC-1 is a predictor for miscarriage in
women [24,25]. MIC-1 is also overexpressed in cancer cells undergoing senescence in
response to chemotherapeutic treatment [26]. These pleiotropic effects of MIC-1
resemble that of TGFb, which is considered as a tumor suppressor during early stages of
cancer and growth/metastasis enhancer at later stages of cancer [27].
This study was initiated to understand the role of AKT in regulating MIC-1
expression and to delineate the consequences of MIC-1 expression on basal and inducible
ERK1/2 and AKT activity in breast cancer cells. We show that AKT directly increases
MIC-1 expression in breast cancer cells through a SP-1 binding site. We also show that
recombinant MIC-1 increases basal ERK1 phosphorylation and prolongs estrogen-
induced ERK1 phosphorylation. These results suggest that MIC-1 serves as an integrator
of AKT and ERK pathways in breast cancer cells.
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4MATERIALS AND METHODS
Breast cancer cells: MCF-7 and ZR-75-1 breast cancer cells were purchased from
American Type Tissue Culture Collection (Manassas, Virginia) and maintained in MEM
plus 10% fetal calf serum.
Recombinant plasmids and transient transfection: MIC-1 promoter corresponding to
nucleotides – 966 to +30 was amplified from the human genomic DNA by polymerase
chain reaction (PCR) and the amplified product was cloned into the chloramphenicol
acetyl transferase reporter vector pBL-CAT3+ [28]. MIC-1 promoter sequences were
verified by sequencing. Promoter deletion mutants were constructed by PCR. SP-1
mutants of MIC-1 promoter were constructed using single-step mutagenesis kit from
Stratagene (Cedar Creek, TX). Cells were harvested 48 h after transfection and CAT
assay was performed as described previously (10). Constitutively active AKT (CA-AKT)
and kinase dead AKT (KD-AKT) constructs have been described previously [10]. MCF-7
cells overexpressing CA-AKT was generated using the bicistronic retrovirus vector
pQXIN (BD Sciences, Palo Alto, CA). All CAT assays were performed three to six
times.
Western blot analysis: Cell lysates were prepared in radioimmunoassay buffer and
subjected to Western analysis as described previously [10]. Phospho-AKT (S473), AKT,
phospho-ERK and ERK antibodies were purchased from Cell Signaling (Beverly, MA).
Recombinant heregulin b 1 and MIC-1 were purchased from R&D systems (Minneapolis,
MN).
Electrophoretic mobility shift assays (EMSA): EMSA was performed using nuclear
extracts from MCF7pQXIN and MCF-7CA-AKT cells. Nuclear extract preparation and
EMSA conditions have been described previously [29]. In competition assays, nuclear
extracts were incubated with unlabelled SP-1 consensus sequence containing
oligonucleotides or –88 to +32 region of the MIC-1 (50 fold access) for 10 minutes on ice
before addition of labeled –88 to +32 region of the MIC-1 promoter. In supershift assays,
nuclear extracts along with probe was incubated with SP-1 or SP-3 antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) for 10 minutes before electrophoresis.
Immunohistochemistry: Sections 4 microns in thickness were deparaffinised and
hydrated. Antigen retrieval was performed in 140mM citrate buffer pH 6.0 in a
decloaking chamber (Biocare) at 125°C for five minutes. The slides were then allowed to
cool for 20 minutes at room temperature. The endogenous peroxidase activity was
blocked by Peroxo-Block (Zymed) for two minutes. The slides were then incubated with
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52% gelatin for 30 minutes to decrease the non-specific staining followed by blocking
endogenous avidin-biotin activity by Avidin-Biotin Blocking kit (Vector Laboratories).
The slides were incubated with 1: 100 goat polyclonal MIC1 antibody (R&D systems) for
one hour at room temperature. For the subsequent steps, the avidin–biotin–peroxidase
method with a Vectastain ABC Elite kit (Vector laboratories) was used according to the
kit instructions. The stain was visualized using Dako liquid DAB plus substrate
chromogen solution and hematoxylin QS (Vector laboratories) counter stain.
Analysis of MIC-1 expression in primary breast cancer by reverse transcription-
polymerase reaction (RT-PCR). Total RNA from tumor tissues or the adjoining normal
tissue was isolated by guanidinium isothiocyanate method. RT-PCR was performed using
the single step RT-PCR kit from Invitrogen. The primers used were 5’-
CGCTCCGCGCGTCGCTGGAAG-3’ and 5’-GGAGCGACTCCCCGGTGTCGG-3’ for
MIC-1; 5’-TGGAGAAACTGCTGCCTCAT-3’ and 5’-
GGAGATGTTGAGCATGTTCA-3’ for 36B4.
Statistical Analysis: Data were analyzed using GraphPad software (Graphpad.com).
Analysis of variance was employed to determine p values between mean measurements.
A p value < 0.05 was deemed significant. Error bars on all histograms in this text
represent standard deviation between measurements from 3-5 experiments.
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6RESULTS
MIC-1 expression is elevated in breast cancer.
We have previously shown elevated expression of MIC-1 in MCF-7 breast cancer
cells overexpressing constitutively active AKT. These cells are also resistant to
tamoxifen. To determine whether MIC-1 is overexpressed in primary breast cancers, we
performed semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) of
RNA isolated from primary breast cancers and adjacent normal tissue. MIC-1 transcript
levels were elevated in primary breast cancer samples compared to adjoining normal
tissues (Fig. 1A). To investigate whether MIC-1 is expressed in cancer cells or stromal
cells, we performed immunohistochemistry of primary tumor samples. Only cancer cells
express MIC-1 (Fig. 1B).
We used MCF-7 cell derived tumors in nude mice to evaluate whether stromal-
cancer cell interaction plays a role in MIC-1 expression. These tumors were obtained
from animals with slow-release estrogen pellets. MCF-7 cells form tumors in nude mice
only when supplemented with estrogen [30]. MCF-7 cells maintained in vitro do not
express MIC-1 [10]. However, MIC-1 was readily detectable in MCF-7 xenografts (Fig.
1C). Thus, it appears that stromal:cancer cell interaction contributes to MIC-1 expression
in cancer cells.
AKT directly increases MIC-1 expression. Because our previous studies have shown a
role for AKT in MIC-1 expression and AKT is activated in breast cancer due to autocrine
and paracrine activity of growth factors, we examined whether AKT directly regulates
MIC-1 promoter activity. Previous studies have identified several regulatory elements in
the MIC-1 promoter [28]. The basal transcription requires three binding sites for SP-
1/SP-3 transcription factors (SP-1A, SP-1B and SP-1C), which are located between –133
to +41 region of the promoter. SP-1B is a perfect SP-1 binding site (GGGCGG) and
binds preferentially to SP-1 and SP-3 whereas SP-1C is an imperfect SP-1 binding site
(AGGCGG) and binds poorly to SP-1 and SP-3. However, it binds strongly to a truncated
SP-3 produced via internal translation initiation [28]. To determine whether AKT utilizes
any of these regulatory elements to increase MIC-1 expression, we transfected MCF-7
breast cancer cells and LnCAP prostate cancer cells with MIC-1/CAT reporter with or
without constitutively active (CA-AKT) or kinase dead AKT (KD-AKT) expression
vector [10]. CA-AKT but not KD-AKT increased MIC-1/CAT expression in both cell
types (Fig.2A). A series of deletion mutants were made to localize the region of MIC-1
promoter required for AKT-mediated activation. Although deletions affected basal
activity of the promoter, AKT-mediated activation was not significantly affected by
deletions. A reporter construct with only –88 to +30 of MIC-1 promoter (-88+30/CAT),
which contains SP-1B and SP-1C sites, was induced by CA-AKT (Fig. 2B). Thus, AKT
 at Pennsylvania State U
niversity on February 23, 2013
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
7responsive element is located within –88 to +30 of MIC-1 promoter, which has been
previously reported to be important for basal expression of the gene [28].
SP-1C element is required for AKT-mediated activation of MIC-1.
To determine the requirements of SP-1 motifs in AKT-mediated activation of
MIC-1 promoter, we mutated SP-1B (MIC1/SP-1Bmut) or SP-1C (MIC1/SP-1Cmut)
sites in the –88+30/CAT reporter. The basal activity of MIC-1/SP-1Bmut was similar to
that of –88+30/CAT and AKT increased its activity (Fig. 3). In contrast, MIC-1/SP-
1Cmut CAT was not efficiently induced by AKT. These results suggest that AKT
increases MIC-1 promoter activity through SP-1C site.
AKT does not alter transcription factor binding to the –88 to +30 region of MIC-1
promoter. To determine whether AKT alters binding of transcription factors to the  -88
to +30 region, we first generated MCF-7 cells overexpressing CA-AKT (MCF-7CA-
AKT) by retrovirus mediated gene transfer. Nuclear extracts from cells with the vector
alone (MCF-7pQXIN) or CA-AKT were used for electrophoretic mobility shift assay
(EMSA) with –88 to +30 as a probe.  Similar DNA binding pattern was observed in both
cell types (Fig. 4A). Intensity of complex I varied from experiments to experiments
(Compare Fig. 4A and B). Unlabelled oligonucleotide containing consensus SP-1 binding
site reduced the intensity of this complex I suggesting that this complex corresponds to
SP-1:DNA complex (Fig. 4B).  Interestingly, competition with unlabelled SP-1
consensus oligonucleotide increased binding of a minor slow mobility complex (indicated
by asterisk).
We used antibody supershift assays to determine whether SP-1 or SP-3 bind to
–88 to +30 region. SP-1 antibody disrupted complex I whereas complex II and III as well
as the minor complex (corresponding asterisk in Fig. 4A) were supershifted by SP-3 (Fig.
4B). Taken together, these results indicate that AKT alters the activity but not binding of
a transcription factor(s) to the –88 to +30 region of the MIC-1 promoter. SP-1 and SP-3
appears to be the major proteins that bind to this region of the promoter.
MIC-1 increases ERK-1 phosphorylation in MCF-7 and ZR-75-1 cells.
ERK pathways play a distinct role in growth and differentiation of breast cancer
cells. For example, transient activation of Raf-MEK-ERK along with activation of AKT
pathway by insulin like growth factor leads to proliferation of MCF-7 cells [31,32].
However, prolonged activation of Raf-MEK-ERK cascade leads to growth inhibition of
these cells. The PI3 kinase/AKT pathway helps in transient Raf-MEK-ERK activation by
downregulating Raf activity through phosphorylation of S259 [8,9]. Anti-estrogens such as
tamoxifen has been shown to induce proliferation instead of inhibiting the growth of
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8MCF-7 cells with elevated basal ERK activity [33]. A recent report suggested that MIC-1
activates PI3 kinase/AKT but represses ERK pathway in neuronal cells [34]. In gastric
cancer cells, however, MIC-1 induces ERK pathway [23].  These contrasting cell type-
specific effects of MIC-1 on ERK prompted us to investigate the effect of MIC-1 on
basal, estrogen and heregulinb1-inducible ERK and AKT activation in MCF-7 cells.
Contrary to neuronal cells, MIC-1 increased basal ERK phosphorylation (Fig. 5A). ERK1
is the major active ERK in MCF-7 cells. Estrogen induced ERK1 in a biphasic manner in
the absence of MIC-1 whereas ERK1 activation was continuous in cells treated with both
estrogen and MIC-1. MIC-1 had a modest effect on heregulin b1-induced ERK activation
(Fig. 5A). We next examined the effect of MIC-1 on AKT activation. MIC-1 had
minimum effect on basal or inducible AKT activation.
We determined the effect of MIC-1 on ERK activation in ZR-75-1 cells to ensure
that the observed effects are not specific to MCF-7 cells. Unlike in MCF-7 cells, both
ERK1 and ERK2 are active in these cells to similar extent (Fig. 5B). Surprisingly,
estrogen reduced phospho-ERK2 levels and altered ratio between phospho-ERK1 and
phospho-ERK2 in favor of phospho-ERK1. MIC-1 pre-treatment accelerated estrogen-
induced shift in phospho-ERK1 and phospho-ERK2 ratio. Neither estrogen nor MIC-1
altered overall levels of ERK1 and ERK2. As with MCF-7 cells, MIC-1 had no effect on
phospho-AKT levels. From these results, we conclude that MIC-1 enhances
phosphorylation status of ERK protein with a specific effect on ERK1. Also, the effect of
MIC-1 on ERK is not negatively regulated by AKT.
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9DISCUSSION
In this report, we show a crosstalk between MIC-1, ERK and AKT in breast
cancer cells. While AKT increased MIC-1 expression, MIC-1 elevated ERK activation.
MIC-1 either alone or in combination with estrogen increased phosphorylation of mostly
ERK1. The role of ERK in growth and differentiation of mammary epithelial cells is still
not clear. Although initial studies indicated a role for ERK in proliferation of mammary
epithelial cells, its activity has been shown to be required for differentiation of breast
cancer cells by agents such as TPA [31]. MCF-7 cells with elevated basal ERK activity
has been shown to growth-stimulated by tamoxifen [33]. AKT pathway on the other hand
is considered a major survival and proliferation pathway for mammary epithelial cells
[8,35]. It is suggested that AKT blocks differentiation of mammary epithelial cells by
inhibiting ERK [8]. The negative crosstalk between AKT and ERK may be abrogated in
cells that overexpress MIC-1 because MIC-1 can induce ERK without reducing AKT and
MIC-1 is induced by AKT.
MIC-1 appears to shift the ratio between active ERK1 and ERK2 in favor of more
active ERK1 (Fig. 5). Consequences of such a shift are not known. Although ERK1 and
ERK2 perform redundant functions, knockout animal studies have revealed unique
functions for ERK1 and ERK2. While ERK2 knockout animals show embryonic lethality
due to defective mesoderm differentiation, ERK1 knockout animals are viable and have a
minor defect in T cell development [36,37]. Although there are no differences in
substrate specificity, ERK1 but not ERK2 binds to scaffold proteins such as MP-1, which
enhances its enzymatic activity [38].  By altering ratio between ERK1 and ERK2, MIC-1
in combination with estrogen can increase the level of enzymatically active species of
ERK. In this regard, we have observed that higher expression of ERK2 than ERK1 in
majority of breast cancer cell lines (data not shown), which may limit the effect of MIC-1
to only those cell types that express higher level of ERK1 compared to ERK2.
AKT increased MIC-1 expression in prostate cancer cells also (Fig. 2). This is
particularly interesting because AKT activation in prostate cancer is associated with poor
clinical outcome [39]. Interestingly, AKT activation in prostate cancer cells leads to
reduced ERK activation, which is similar to the effect of MIC-1 on ERK in neuronal cells
[34]. MIC-1 overexpression in prostate cancer is correlated with invasiveness and
metastasis [40,41]. A recent protein profiling of microdissected prostate tissue revealed
overexpression of MIC-1 protein in high-grade prostatic intraepithelial neoplasia and
prostate cancer cells of Gleason grade 3 [42]. Additional studies are required whether
AKT action in prostate cancers is mediated through induction of MIC-1.
The mechanism by which AKT increases MIC-1 expression is not known. The
basal MIC-1 promoter activity is dependent on three SP-1 response elements; SP-1A, SP-
B and SP-1C [28]. SP-1B is a perfect SP-1 binding site whereas SP-1A and SP-1C are
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10
imperfect SP-1 binding sites. SP-1A site is not involved in AKT-mediated activation of
MIC-1 because this site is upstream of the minimum region of the promoter required for
AKT-mediated activation. Furthermore, a reporter containing –966 to +30 promoter
region of MIC-1 with SP-1A mutation was activated by AKT (data not shown). SP-1C is
involved in AKT-mediated activation of MIC-1. SP-1 has previously been linked to
AKT-mediated activation of FRA-1 [43]. Activation of FRA-1 by AKT involved
transcriptional upregulation and increased DNA binding of SP-1 [43]. However, that is
not the case with MIC-1 promoter because we did not observe increased SP-1 binding in
cells overexpressing CA-AKT. SP-1C binds preferentially to truncated SP-3 [28]. We
also observed preferential binding of SP-3 to the MIC-1 promoter region that respond to
AKT (Fig. 4B). We believe that AKT increases interaction of SP-3 bound to SP-1C site
with transcriptional co-activators or other transcription factors. One such candidate is
ERa , which indirectly activates promoters through interaction with SP-1 [44] and is
phosphorylated by AKT [10]. In our previous study, we have shown estrogen-dependent
increase in MIC-1 in MCF-7 cells overexpressing CA-AKT [10]. In addition, a number
of co-regulators are phospho-proteins and some of them may be target of AKT [45,46].
COUP-TF nuclear receptors have previously been shown to increase MIC-1 expression
through SP-1 binding sites [28]. However, COUP-TFs are not likely to be the target of
AKT because they lack consensus AKT phosphorylation sites and we did not observe
synergistic increase in MIC-1 expression upon co-expression of COUP-TFs and AKT
(data not shown). Also note that both SP-1 and SP-3 lack consensus AKT
phosphorylation sites.
The role of MIC-1 in cancer progression is unclear if not controversial. We
observed MIC-1 expression in primary breast cancer and a recent study showed rapid
induction of MIC-1 in cancer cells subsequent to neo-adjuvant therapy [47]. MIC-1 has
been linked to senescence and apoptosis of cancer cells [18,26]. It is also overexpressed
in cancer cells that are sensitive to chemotherapy but not in cancer cells that are resistant
to chemotherapy [26]. In contrast to these pro-cell death function, MIC-1 overexpression
is linked to progression of gastric cancer [23]. This paradoxical role of MIC-1 in cancer
could be related to its ability to induce ERK. Depending on the cell type and duration of
induction, ERK can induce cell cycle arrest, senescence, or drug resistance [33,48,49].
Thus, in cancer types in which ERK induces growth arrest or senescence, MIC-1 may
play a pro-death role. Similarly, MIC-1 expression may be linked to sensitivity to
chemotherapy in cancers where chemotherapy-induced cell death requires ERK
activation [50]. Rapidly proliferating cells are more sensitive to chemotherapy compared
to quiescent cells. MIC-1 may sensitize certain cancer cells to chemotherapy by
increasing their proliferation. In cancers where ERK activation is linked to survival
through AP-1 pathway, MIC-1 may play a role in progression of cancer. MIC-1 mediated
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11
upregulation of urokinase plasminogen activator in gastric cancer cells could be a
consequence of AP-1 activation [23]. With respect to breast cancer, we suspect that MIC-
1 plays a role in cancer progression, particularly in estrogen receptor alpha (ERa )-
positive breast cancers because it induces ERK without reducing AKT. Both ERK and
AKT modulate ERa activity [51]. We observed MIC-1 expression in MCF-7 cell-derived
tumors in nude mice (Fig. 1C), which suggests a correlation between proliferation and
MIC-1 expression. Elevated MIC-1 in serum of patients with metastatic breast cancer
may be indicate rate of proliferation of cancer cells at sites of metastasis [21]. Additional
immunohistochemical studies with tissues obtained from sites of metastasis are required
to test this possibility.
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FIGURE LEGEND
Fig. 1: MIC-1 expression in primary breast cancer. A) MIC-1 transcripts in breast
cancer homogenate as well as in adjoining tissues of some tumors were measured by RT-
PCR (35 cycles). The integrity and equal quantity of RNA in each reaction were verified
by RT-PCR using primers specific to the housekeeping gene 36B4 (20 cycles). B)
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Immunohistochemistry reveals expression of MIC-1 in cancer cells but not stromal cells.
C) MIC-1 is expressed in tumors derived from MCF-7 cells in nude mice.
Fig. 2: AKT increases MIC-1 expression. A) CA-AKT but not KD-AKT increases
MIC-1 promoter/reporter activity in MCF-7 cells. MCF-7 cells were transfected with a
CAT reporter containing sequences –966 to +30 of MIC-1 promoter (10 µg) with or
without constitutively active (CA-AKT) or kinase dead AKT (KD-AKT). The empty
expression vector pCDNA3 (0.5 µg) was included in the control. The transfection
efficiency was measured using RSV-b-galactosidase expression vector (2 µg). CAT
activity in equal number of b-galactosidase units was measured 48 h after transfection.
CA-AKT increased MIC-1 promoter activity in LnCAP cells. B) The AKT response
element is located within the –88 to +30 region of MIC-1 promoter. A series of deletion
MIC-1 promoter constructs were transfected into MCF-7 cells with or without CA-AKT
as above and CAT activity was measured 48 h after transfection. Note that CA-AKT had
no effect on residual expression of pBL-CAT3+ reporter, which lacks any
enhancer/promoter region as well as pBL-CAT2+ reporter, which contains HSV TK
promoter but not enhancer (data not shown).
Fig. 3: SP-1C element is required for AKT-mediated activation of MIC-1. The
–88/+30 MIC-1 CAT reporter with mutation in SP-1B (MIC-1/SP-1Bmut) or SP-1C
(MIC-1/SP-1Cmut) were co-transfected with either the empty vector pcDNA3 or CA-
AKT. CAT activity was measured as in Fig. 2.
Fig. 4: AKT does not alter transcription factor binding to –88 to +30 region of MIC-
1 promoter in vitro. A) Electrophoretic mobility shift assay was performed with nuclear
extracts from MCF-7pQXIN (control) or MCF-7CA-AKT cells. The –88 to +30 region of
MIC-1 promoter was used as probe. Intensity of complex I was reduced by unlabelled
oligonulceotide containing consensus SP-1 binding site identical to SP-1B element. An
asterisk indicates a minor complex whose intensity increased upon competition with
unlabelled SP-1 consensus oligonucleotide. B) Binding of SP-1 and SP-3 to –88 to +30
region of MIC-1 was determined by antibody supershift assays. While SP-1 antibody
disrupted complex I, SP-3 antibody supershifted complex II, III and the minor complex.
SS= supershift.
Fig. 5: The effect of MIC-1 on ERK and AKT activity in MCF-7 and ZR-75-1 cells.
A) MIC-1 increases phospho-ERK1 levels in MCF-7 cells. MCF-7 cells serum starved
for 48 h were incubated with recombinant MIC-1 (25 ng/ml) for one h followed estrogen
(10-10 M) or heregulin b1 (50 ng/ml) for indicated time. Activated ERK and AKT levels
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were measured using phospho-specific ERK and phospho-AKT (S473) antibodies,
respectively. The same blot was reprobed with antibodies that measure total ERK or
AKT. Note that MIC-1 increased basal phospho-ERK levels as well as caused sustained
instead of biphasic ERK activation in estrogen treated cells. MIC-1 had only a modest
effect on heregulin b 1-induced ERK. B) MIC-1 increases ERK1 phosphorylation in ZR-
75-1 cells and modulates estrogen-mediated changes in phospho-ERK1 and phospho-
ERK2 ratio.
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